HEMATOLOGIC CHANGES OBSERVED FOLLOWING I$sup 131$ THERAPY FOR THYROID CARCINOMA

Journal Article · Fri Mar 01 04:00:00 EST 1963 · Journal of Nuclear Medicine (U.S.)

OSTI ID:4755722

Haynie, T P; Beierwaltes, W H

Two hundred patients received therapy doses of I/sup 131/ for thyroid carcinoma in the interval 1947 to 1960. Follow-up evaluations of the peripheral blood were made at three months and at yearly intervals up to ten years after completion of therapy in 159 patients. The most common abnormality observed in the peripheral blood count after I/sup 131/ therapy was a subnormal hemoglobin concentration seen in 36% of the patients. Subnormal white blood counts were seen in about 10% of the patients, and thrombocytopenia was seen in only five cases (3%). These changes were roughly correlated with the total dose of I/sup 131/ in that those who had blood abnormalities noted after treatment received about twice the mean total dose of those who did not experience abnormality. In addition, the extent of metastatic disease and the administration of preceding x- ray therapy were of importance in producing blood changes after I/sup 131/. These changes were of brief duration, for the most part lasting less than one year, and were not symptomatic. No cases of leukemia or aplastic anemia have been observed to date. (auth)

• Research Organization: Univ. of Michigan, Ann Arbor
• NSA Number: NSA-17-015696
• OSTI ID: 4755722
• Journal Information: Journal of Nuclear Medicine (U.S.), Journal Name: Journal of Nuclear Medicine (U.S.) Vol. Vol: 4; ISSN JNMEA
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

BIOLOGY AND MEDICINE
BLOOD CELLS
CANCER
HEMOGLOBIN
IODINE 131
LEUCOCYTES
MAN
METASTASES
PLATELETS
QUANTITY RATIO
RADIATION DOSES
RADIATION EFFECTS
RADIOTHERAPY
THYROID
VARIATIONS
X RADIATION